The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats

QR Code

The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats

Adel Ali Albanna,1 Doa’a Anwar Ibrahim,2 Amani Mohammed Shamsher,3 Mojahed Ali Al-Shawia,4 Abdulsalam Halboup1,5 1Department of Pharmacology, Faculty of Pharmacy, University of Science and Technology, Sana’a, Yemen; 2Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Univers...

Full description

Saved in:

Bibliographic Details
Main Authors:	Albanna AA, Ibrahim DA, Shamsher AM, Al-Shawia MA, Halboup A
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-07-01
Series:	Journal of Experimental Pharmacology
Subjects:	Dapagliflozin Liraglutide Cardio-Renal Injuries.
Online Access:	https://www.dovepress.com/the-potential-effect-of-dapagliflozin-and-liraglutide-in-attenuating-c-peer-reviewed-fulltext-article-JEP
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cardio-renal interrelation: modern view
by: Zh. D. Kobalava, et al.
Published: (2010-08-01)

Liraglutide Attenuates Atorvastatin-Induced Hepatotoxicity by Restoring GLP-1R Expression and Activating Nrf2 and Autophagy Pathways in Wistar Rats
by: Engy A. Elsiad, et al.
Published: (2025-07-01)

FUNCTIONAL STATUS OF HEART AND KIDNEYS AND CARDIO-RENAL INTERACTIONS IN PATIENTS AFTER CORONARY REVASCULARISATION INTERVENTION
by: M. E. Statsenko, et al.
Published: (2012-12-01)

The effect of liraglutide on metabolic and reproductive outcomes in infertile women with PCOS: A prospective cohort study
by: Rossella Cannarella, et al.
Published: (2025-09-01)

The Effect of Dapagliflozin, a Sodium–Glucose Co-Transporter 2 Inhibitor, on Vancomycin-Induced Nephrotoxicity in Rats
by: Seyhmus Tan, et al.
Published: (2025-06-01)

The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
by: V. Yu. Perfil’ev, et al.
Published: (2017-04-01)

Dapagliflozin alleviates mitochondrial damage in the myocardium under diabetic conditions by targeting sortilin
by: Yifeng Gao, et al.
Published: (2025-06-01)

EFFECT OF RENAL DYSFUNCTION ON THE CARDIACVASCULAR SYSTEM. THE POSSIBILI TIES OF EARLY DIAGNOSIS OF THE RENAL DYSFUNCTION
by: B. Zh. Imanov, et al.
Published: (2018-08-01)

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
by: S. V. Nedogoda
Published: (2018-05-01)

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial
by: Zhuoshan Huang, et al.
Published: (2025-08-01)

A meta-analysis of the effects of finerenone on cardio-renal outcomes in patients with type 2 diabetes mellitus or chronic kidney disease
by: Liu Jing, et al.
Published: (2025-06-01)

Association of oxidative balance score with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease
by: Yucui Lin, et al.
Published: (2025-06-01)

Efficacy and Safety of Liraglutide in Adolescents Aged 12–15 Years with Obesity: a Prospective 24-week Observational
by: Olga P. Kovtun, et al.
Published: (2025-05-01)

Pretreatment GFR Slopes Predict Dapagliflozin Response in IgA Nephropathy
by: Hiroyuki Ueda, et al.
Published: (2025-07-01)

Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide
by: A. S. Ametov, et al.
Published: (2023-11-01)

Optimization and validation of UPLC method for dapagliflozin and candesartan cilexetil in an on-demand formulation: Analytical quality by design approach
by: Elzayat Ehab M., et al.
Published: (2025-07-01)

Compare the Decrease in Visceral Adipose Tissue in People with Obesity and Prediabetes vs. Obesity and Type 2 Diabetes Treated with Liraglutide
by: Rosa Nayely Hernández-Flandes, et al.
Published: (2025-07-01)

Arterial Hypertension in Cardio-Renal-Metabolic Syndrome: New Targets and Proven Treatment Approaches
by: S. R. Gilyarevsky
Published: (2025-06-01)

De la suma de los factores a la sinergia de los daños: hacia una redefinición del síndrome cardio-reno-metabólico
by: Florencia Aranguren
Published: (2025-06-01)

LC-MS-Based Untargeted Metabolic Profiling in Plasma Following Dapagliflozin Administration in Healthy Volunteers
by: Hyeon Ji Kim, et al.
Published: (2025-07-01)

The efficacy of liraglutide-based drugs on the model of induced metabolic syndrome in experimental animals
by: A. A. Andreev-Andrievsky, et al.
Published: (2025-08-01)

Effect of dapagliflozin on serum N‐terminal fragment-proB‐type natriuretic peptide level in patient with acute decompensated heart failure
by: Hanna Jassim Dohei, et al.
Published: (2025-03-01)

Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
by: Huiyuan Zhang, et al.
Published: (2025-07-01)

Vegetative provision of the cardio-vascular system while orthostatic sportsmen testing
by: O. N. Kudrya
Published: (2010-06-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Telehealth consultations in cardio-oncology
by: V. I. Potievskaya, et al.
Published: (2022-02-01)

Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
by: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
Published: (2025-06-01)

Reparative effects of paricalcitol and calcitriol in patients with cardiorenal syndrome and chronic allograft nephropathy
by: A. N. Kharlamov, et al.
Published: (1970-01-01)

Cardio-metabolic risk factors and insulin resistance
by: O.Ye. Sklyarova, et al.
Published: (2025-05-01)

Qualitative and Quantitative Determination of Dapagliflozin Propanediol Monohydrate and Its Related Substances and Degradation Products Using LC-MS and Preparative Chromatography Methods
by: Ali Ismail, et al.
Published: (2023-10-01)

Safety and Efficacy of Dapagliflozin in Patients With Systemic Right Ventricular Dysfunction: DAPA‐SRV Trial
by: Mathieu Albertini, et al.
Published: (2025-06-01)

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)

Left ventricular function in patients with cardiorenal pathology and chronic renal failure
by: M. M. Dudar, et al.
Published: (2006-06-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice
by: M. M. Loukianov, et al.
Published: (2020-03-01)

Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction—DAPA-STEMI Trial
by: Luis Ortega-Paz, et al.
Published: (2025-06-01)

CARDIO-ANKLE VASCULAR INDEX IN PATIENTS WITH CORONARY HEART DISEASE: ROLE OF PERIPHERAL ATHEROSCLEROSIS
by: A. N. Sumin, et al.
Published: (2013-10-01)

CARDIO-ANKLE VASCULAR INDEX IN PATIENTS WITH CORONARY HEART DISEASE: ASSOCIATION WITH THE SEVERITY OF CORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS
by: A. N. Sumin, et al.
Published: (2012-04-01)

Euglycemic diabetic ketoacidosis and a probable Fanconi syndrome secondary to dapagliflozin: a case report
by: Luis E. Fernández-Garza, et al.
Published: (2025-07-01)